For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Goodfellow gems #143
Wednesday 17 March 2021, 12:45 AM

“New twice-daily nitrofurantoin (Macrobid) now available in New Zealand”
Nitrofurantoin is now a first-line antibiotic for cystitis, through its high concentration in urine, and is active against most urinary pathogens. It
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
1. doi.org/10.1093/jac/dkv147 (J Antimicrob Chemother 2015;70(9):2456–64).
2. doi. org/10.18773/austprescr.2019.002 (Aust Prescr 2019;42(1):14–19).